skip to main content

Dantrolene RYR1 — FRCA Primary MCQ

Instant feedback + full explanation. One question, done properly.

ModeratePharmacology - General PrinciplesDantrolene RYR1FRCA Primary

Dantrolene treats malignant hyperthermia by:

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: CInhibiting calcium release from the sarcoplasmic reticulum via the ryanodine receptor

Dantrolene inhibits calcium release from the SR by acting on the RYR1 receptor. In MH a mutation causes excessive calcium release triggered by volatile agents or suxamethonium. Initial dose is 2.5 mg/kg IV repeated to 10 mg/kg.

Reference: Peck Hill Williams 2014 Pharmacology for Anaesthesia and Intensive Care